Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29903740 | 0.80 | PDE4B (0.34) | CYP17A1CYP1A2CYP3A4HSD17B10TDP1 | |
| SCHEMBL20345724 | 0.80 | CYP17A1 (0.37) | CYP17A1CYP1A2CYP3A4HSD17B10TDP1 | |
| SCHEMBL31189713 | 0.80 | CYP17A1 (0.34) | CYP17A1CYP1A2CYP3A4HSD17B10TDP1 | |
| SCHEMBL6245196 | 0.79 | — | — | |
| SCHEMBL907751 | 0.78 | TNFSF11 (0.41) | CYP17A1CYP3A4HSD17B10TDP1ALDH1A1 | |
| SCHEMBL29728856 | 0.77 | CYP17A1 (0.35) | CYP17A1CYP1A2CYP3A4HSD17B10TDP1 | |
| SCHEMBL30361260 | 0.77 | CYP1A2 (0.37) | CYP17A1KMT2ACYP1A2CYP3A4HSD17B10 | |
| SCHEMBL6165930 | 0.77 | CYP2B6 (0.36) | CYP17A1CYP1A2CYP3A4HSD17B10TDP1 | |
| SCHEMBL26453885 | 0.77 | CYP1A2 (0.37) | CYP17A1KMT2ACYP1A2CYP3A4HSD17B10 | |
| SCHEMBL9965937 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120058790-A | Preparation method of novel phosphorus-containing agricultural compound synergist and application of novel phosphorus-containing agricultural compound synergist in agriculture | 贵州工业职业技术学院 | 2025-05-30 | — | — | CN | claimed |
| CN-120058790-A | Preparation method of novel phosphorus-containing agricultural compound synergist and application of novel phosphorus-containing agricultural compound synergist in agriculture | 贵州工业职业技术学院 | 2025-05-30 | — | — | CN | disclosed |
| CN-120058790-A | Preparation method of novel phosphorus-containing agricultural compound synergist and application of novel phosphorus-containing agricultural compound synergist in agriculture | 贵州工业职业技术学院 | 2025-05-30 | — | — | CN | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PFIZER INC. (US) | 2023-01-24 | — | — | US | disclosed |
| CN-217092184-U | Activated carbon decoloring device for precisely processing sulfadoxine | 江苏金申医药科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-110694319-B | High-purity decolorizing and filter pressing process of sulfadoxine | 江苏金申医药科技有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-110642794-B | Efficient preparation method of sulfadoxine cyclic compound intermediate | 江苏金申医药科技有限公司 | 2022-03-08 | — | — | CN | disclosed |
| EP-3374350-B1 | HYDROXYPYRIDINONE AND HYDROXYPYRIMIDINONE BASED COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | FORGE THERAPEUTICS INC (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-3374350-B1 | HYDROXYPYRIDINONE AND HYDROXYPYRIMIDINONE BASED COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | FORGE THERAPEUTICS INC (US) | 2022-01-05 | — | — | EP | disclosed |
| CN-213790374-U | Filtration equipment is used in methyl methoxyacetate production | 十堰御晨生物科技有限公司 | 2021-07-27 | — | — | CN | disclosed |
| US-20210078957-A1 | SUBSTITUTED PYRIMIDINES FOR TREATING BACTERIAL INFECTIONS | FORGE THERAPEUTICS, INC. | 2021-03-18 | — | — | US | disclosed |
| US-20210078957-A1 | SUBSTITUTED PYRIMIDINES FOR TREATING BACTERIAL INFECTIONS | FORGE THERAPEUTICS, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10875832-B2 | Substituted pyrimidines for treating bacterial infections | FORGE THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10875832-B2 | Substituted pyrimidines for treating bacterial infections | FORGE THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10414735-B2 | Substituted hydroxypyrimidinones for treating bacterial infections | FORGE THERAPEUTICS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10414735-B2 | Substituted hydroxypyrimidinones for treating bacterial infections | FORGE THERAPEUTICS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180327365-A1 | HYDROXYPYRIDINONE AND HYDROXYPYRIMIDINONE BASED COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | BLACKSMITH MEDICINES, INC. | 2018-11-15 | — | — | US | disclosed |
| EP-3374350-A2 | HYDROXYPYRIDINONE AND HYDROXYPYRIMIDINONE BASED COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | Forge Therapeutics, Inc. (US) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017083431-A2 | HYDROXYPYRIDINONE AND HYDROXYPYRIMIDINONE BASED COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | FORGE THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PDE4B, PDE4A, PDE3B | CYP17A1 94/4885KMT2A 2476/4885CYP1A2 391/4885 |
| US-20210078957-A1 | SUBSTITUTED PYRIMIDINES FOR TREATING BACTERIAL INFECTIONS | DPYD, TYMP, UMPS | CYP17A1 2668/4885KMT2A 2877/4885CYP1A2 1566/4885 |
| US-10414735-B2 | Substituted hydroxypyrimidinones for treating bacterial infections | ALPI, HPGDS, SDHB | CYP17A1 106/4885KMT2A 3605/4885CYP1A2 79/4885 |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | CYP17A1 115/4885KMT2A 1626/4885CYP1A2 1070/4885 |
| US-20180327365-A1 | HYDROXYPYRIDINONE AND HYDROXYPYRIMIDINONE BASED COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | HPGDS, DHPS, GMPS | CYP17A1 642/4885KMT2A 2382/4885CYP1A2 758/4885 |
| US-10875832-B2 | Substituted pyrimidines for treating bacterial infections | UMPS, DPYD, TYMP | CYP17A1 1711/4885KMT2A 2762/4885CYP1A2 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.